Table 1.
Main characteristics of 19 studies included in meta-analysis.
| First Author and Year | Country | Patients (N) | Design | Age (mean ± SD) | Gender (M) | Sample Size (N) | Gross Total Resection (N) | Second Surgery (N) | NLR Cut-off | Therapy | Outcome | HR (95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bambury 2013 | USA | GBM multiforme | Retrospective | 56.6 ± 11.53 | 65 | 84 | 23 | NR | NLR = 4 | S + C+ T | MA | 1.81 (1.08–3.02) |
| Sheng Han 2015 | China | GBM | Retrospective | 50.4 ± 15.4 | 95 | 152 | 75 | NR | NLR = 4 | S + C | MA | 2.068 (1.304–3.277) |
| Peng-Fei Wang 2017 | China | GBM | Prospective | 52.1 ± 0.984 | 96 | 166 | 102 | NR | NLR = 4 | NR | MA | 1.712 (1.026–2.858) |
| Marta Lopes 2018 | Portugal | GBM multiforme | Retrospective | NR | NR | 126 | NR | NR | NLR = 5 | NR | MA | 1.56 (1.04–2.34) |
| Weiji Weng 2018 | China | GBM | Retrospective | NR | 53 | 105 | 57 | NR | NLR = 4 | S + C+ T | NR | 1.953 (1.255–3.039) |
| Peng-Fei Wang 2018 | China | GBM | Retrospective | NR | NR | 314 | NR | NR | NR | NR | UA | 0.57 (0.41–0.79) |
| ÖZLEM YERSAL 2018 | Turkey | GBM | Retrospective | 56.8 ± 13.1 | 39 | 80 | 42 | NR | NLR = 4 | S + C+ T | UA | 1.258 (0.727–2.179) |
| SybrenL.N. Maas 2019 | Netherlands | GBM | Retrospective | NR | NR | 479 | NR | NR | NLR = 4 | NR | MA | 1.11 (0.75–1.65) |
| Yajuan Lv 2019 | China | GBM | Retrospective | 53.25 ± 13.9 | 113 | 192 | NR | NR | NLR = 2.7 | NR | MA | 0.637 (0.454–0.894) |
| Yunfei Hao 2019 | China | GBM multiforme | Retrospective | 55 ± 13.55 | 116 | 187 | 112 | NR | NLR = 4.1 | S + C+ T | UA | 2.574 (1.849–3.581) |
| Agam Brenner 2019 | Israel | GBM multiforme | Retrospective | 57.73 ± 12.43 | 46 | 89 | 59 | 23 | NLR = 4 | S + C+ T | MA | 0.856 (0.49–1.496) |
| Ozlem MERMUT 2020 | Turkey | GBM multiforme | Retrospective | 58.0 ± 13.02 | 47 | 75 | 31 | NR | NLR = 4 | NR | MA | 2.14 (1.11–4.14) |
| Alessandra Marini 2020 | Italy | GBM | Retrospective | NR | 65 | 124 | 64 | NR | NLR = 4 | S + C | MA | 1.58 (1–2.49) |
| Mehmet Besiroglu 2021 | Turkey | GBM multiforme | Retrospective | 47.2 ± 12.1 | 58 | 107 | 73 | NR | NLR = 2.9 | S + C+ T | MA | 1.38 (0.87–2.17) |
| Anne Clavreul 2021 | France | GBM | Retrospective | 61.5 ± 8.8 | 65 | 85 | 46 | NR | NLR = 2.06 | S + C+ T | NR | 1.67 (1.03–2.71) |
| Vildan Kaya 2017 | Antalya | GBM | Retrospective | 55.7 ± 16.3 | NR | 90 | NR | NR | NLR = 5 | NR | MA | 2.41 (1.26–4.58) |
| Zhen-Yu Zhang 2019 | China | GBM | Retrospective | NR | NR | 170 | NR | NR | NLR = 7.25 | NR | MA | 2.228 (1.329–3.733) |
| Xing-Wang Zhou 2016 | China | GBM | Retrospective | 52.85 ± 4.03 | 50 | 84 | 59 | NR | NLR = 4 | C | UA | 1.264 (0.785–2.035) |
| Qian He 2021 | China | GBM | Retrospective | NR | NR | 62 | 46 | NR | NLR = 3.31 | S + C | UA | 1.766 (0.941–3.316) |
Note: UA: univariate analysis; MA: multivariate analysis; S + C + T: Stupp + chemoradiotherapy + temozolomide; NLR: neutrophil count/lymphocyte count; HR: hazard ratio; CI: confidence interval; NR: not reported; NOS: Newcastle-Ottawa quality assessment.